SCHEMBL6327236

SCHEMBL6327236

COc1ccc(C(CCCN(Cc2ccccc2)C[C@H](O)COc2ccc(OCc3ccccc3)c(N)c2)c2ccc(OC)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.52
TSHR P16473 1/20 0.52
POLB P06746 3/20 0.47
NPC1 O15118 2/20 0.47
NR1H3 Q13133 6/20 0.47
MAPT P10636 4/20 0.44
GAA P10253 1/20 0.44
MAPK1 P28482 1/20 0.44
NPSR1 Q6W5P4 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
ABCB1 P08183 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KCNH2 Q12809 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320375 0.95 ALDH1A1 (0.54) ALDH1A1TSHRPOLBNPC1NR1H3
SCHEMBL7612133 0.95 ALDH1A1 (0.54) ALDH1A1TSHRPOLBNPC1NR1H3
SCHEMBL7606888 0.90 ALDH1A1 (0.52) ALDH1A1TSHRPOLBNPC1NR1H3
SCHEMBL6320449 0.89 NR1H3 (0.47) ALDH1A1TSHRPOLBNPC1NR1H3
SCHEMBL6320445 0.89 NR1H3 (0.47) ALDH1A1TSHRPOLBNPC1NR1H3
SCHEMBL7612298 0.88 ALDH1A1 (0.50) ALDH1A1TSHRPOLBNPC1MAPT
SCHEMBL7611642 0.84 ALDH1A1 (0.52) ALDH1A1TSHRPOLBNPC1NR1H3
Hydrochloric Acid SCHEMBL6320402 0.84 ALDH1A1 (0.62) ALDH1A1TSHRPOLBNPC1NR1H3
SCHEMBL6322792 0.84 NPC1 (0.46) ALDH1A1TSHRPOLBNPC1NR1H3
SCHEMBL7610964 0.84 NPC1 (0.46) ALDH1A1TSHRPOLBNPC1NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043371-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-02-24 US disclosed
US-20030181726-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-25 US disclosed
EP-1107944-A1 AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-06-20 EP disclosed
WO-2000012462-A1 AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043371-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists ADRB1, ADRB3, ADRB2 ALDH1A1 197/4885TSHR 3883/4885POLB 995/4885
US-20030181726-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists ADRB1, ADRB3, ADRB2 ALDH1A1 183/4885TSHR 3757/4885POLB 993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.